Single Use Bioprocessing Global Market Report 2024

Single-use bioprocessing refers to the use of bioprocessing equipment designed for one-time use and subsequent disposal. These products are typically constructed from plastic components that undergo sterilization through gamma radiation. Single-use bioprocessing offers advantages such as saving time spent on cleaning, reducing water usage, and lowering energy consumption. This approach is applied across the bioproduction workflow to minimize the risk of cross-contamination.

The primary product types in the single-use bioprocessing market include single-use media bags and containers, single-use assemblies, single-use bioreactors, disposable mixers, and other related products. Single-use media bags and containers serve the purpose of containing sterile media, cell cultures, sera, buffers, and reagents. These containers are designed for one-time use and subsequent disposal. The workflows in which single-use bioprocessing is employed include upstream, fermentation, and downstream processes. Various applications of single-use bioprocessing include filtration, storage, cell culture, mixing, and purification. This approach is adopted by biopharmaceutical and pharmaceutical companies, contract research organizations, contract manufacturing organizations (CROs and CMOs), as well as academic and research institutes.

The single-use bioprocessing market research report is one of a series of new reports that provides single-use bioprocessing market statistics, including single-use bioprocessing industry global market size, regional shares, competitors with a single-use bioprocessing market share, detailed single-use bioprocessing market segments, market trends and opportunities, and any further data you may need to thrive in the single-use bioprocessing industry. This single-use bioprocessing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The single use bioprocessing market size has grown rapidly in recent years. It will grow from $22.34 billion in 2023 to $26.71 billion in 2024 at a compound annual growth rate (CAGR) of 19.6%. The growth observed in the historical period can be attributed to several factors, including increased biopharmaceutical production, advancements in biotechnology and cell culture processes, the desire to reduce cross-contamination risks, adherence to regulatory compliance in bioprocessing, and the demand for cost-effective solutions in the field of bioprocessing.

The single use bioprocessing market size is expected to see exponential growth in the next few years. It will grow to $55.84 billion in 2028 at a compound annual growth rate (CAGR) of 20.2%. The anticipated growth in the forecast period can be attributed to various factors, including the expansion of personalized medicine, increased production of gene and cell therapies, the adoption of continuous bioprocessing, biomanufacturing for rare diseases, the expansion of biosafety levels, and the development of emerging markets and global biomanufacturing hubs. Key trends expected in the forecast period include the adoption of automated and robotic single-use systems, the integration of single-use sensors and analytics, the implementation of closed-system aseptic filling and packaging, the construction of modular and scalable bioprocessing facilities, the emergence of on-demand and decentralized biomanufacturing models, and the utilization of virus filtration and purification solutions in the bioprocessing industry.

The anticipated increase in demand for biopharmaceuticals is set to drive the growth of the single-use bioprocessing market in the future. Biopharmaceuticals, which are medications derived from living cells or organisms, witness a widespread application in the healthcare industry. Single-use bioprocessing systems play a crucial role in biopharmaceutical manufacturing, contributing to heightened productivity, cost savings, and the environmentally friendly disposal of waste. In 2021, pharmaceutical production in Europe reached $351 billion (€300,000 million), marking a 5% increase from the previous year, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA). This surge in biopharmaceutical demand is a key driver for the growth of the single-use bioprocessing market.

The escalation of chronic diseases is poised to be a significant factor propelling the growth of the single-use bioprocessing market. Chronic diseases, characterized by prolonged medical conditions lasting three months or more, necessitate ongoing treatment. Single-use bioprocessing technologies are instrumental in the manufacturing of biopharmaceuticals used to combat chronic diseases such as diabetes, cancer, and autoimmune disorders. The prevalence of chronic illnesses is expected to rise by 99.5%, reaching 142.66 million individuals aged 50 years and older by 2050 in the United States, as reported by the National Library of Medicine. This demographic shift towards chronic diseases is expected to contribute substantially to the expansion of the single-use bioprocessing market.

A noteworthy trend in the single-use bioprocessing market involves technological advancements that major industry players are adopting to maintain a competitive edge. For example, Cytiva, a U.S.-based company, introduced X-platform bioreactors designed to enhance efficiency in single-use upstream bioprocessing. These bioreactors, ranging in size from 50 to 200 liters, come equipped with the Figurate automation solution software, improving process efficiency, increasing production capacity, and streamlining supply chain operations.

Innovation is a key focus for major companies in the single-use bioprocessing market, exemplified by products like Ultimus Single-Use Process Container Film. This innovation, integrated into Merck Group's Mobius 3D process containers, provides exceptional durability and leak resistance for single-use assemblies in bioprocessing liquid applications. The film features a unique woven nylon structure, offering enhanced bag strength and improved resilience to issues like abrasions, tears, and material fatigue.

In a strategic move, in June 2021, Avantor Inc., a U.S.-based chemicals and materials manufacturer, acquired RIM Bio, a China-based manufacturer of single-use bioprocess bags and assemblies, This acquisition enhances Avantor's single-use manufacturing portfolio in the AMEA region, better serving the growing demand for single-use bioprocessing solutions.

Major companies operating in the single use bioprocessing market include GE Healthcare Technologies Ltd., Eppendorf AG, Corning Incorporated, Thermo Fisher Scientific Inc., Sartorius AG, JM BioConnect BV, Merck KGaA, Pall Corporation, Kuhner AG, PBS Biotech Inc., Entegris Inc., DistriCell Inc., ABEC Inc., Able Corporation and Biott Corporation, Solida Biotech GmbH, OmniBRx Biotechnologies Pvt. Ltd., Satake Chemical Equipment Mfg. Co. Ltd., Stobbe Pharma GmbH, Celltainer Biotech BV, Cellexus BV, Danaher Corporation, Boehringer Ingelheim International GmbH, General Electric Company, Rentschler Biopharma SE, Repligen Corporation, Sollesis Medical PLC, Charter Medical Inc., Secant Group LLC, Lonza Group Ltd., Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., Catalent Inc., Patheon Inc., Bio-Rad Laboratories Inc., Avantor Performance Materials India Limited, MilliporeSigma, Saint-Gobain Performance Plastics Corp., Meissner Filtration Products Inc.

North America was the largest region in the single-use bioprocessing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single use bioprocessing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the single use bioprocessing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The single-use bioprocessing market includes revenues earned by entities by bioreactors, tangential-flow filtration devices, depth filters, disposable filter cartridges, media bags and containers, mixing systems, tubing assemblies and sampling systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.